The U.S. Patent and Trademark Office (USPTO) recently issued a
new U.S. patent (Patent No. 8,617,600) to
Supernus Pharmaceuticals, Inc.
) antiepileptic drug, Oxtellar XR.
The patent, which will not expire before 2027, will protect
Oxtellar XR from generic threat. This new patent boosts the
existing patent portfolio of Oxtellar XR, which already has two
In Feb 2013, Supernus launched Oxtellar XR in the U.S. The
company reported meaningful growth in the Oxtellar XR prescriber
base in the third quarter of 2013, totaling 7,596, up from 3,648
in the second quarter. Since its launch, more than 1,600 target
physicians have prescribed Oxtellar XR. Recognized revenue for
Oxtellar XR in the first nine months of 2013 was $1.3 million.
Deferred revenues at the end of Sep 2013 were $6.6 million.
Supernus expects revenues of $8.5 million for Oxtellar XR in
Last month, Supernus presented data on Oxtellar XR at the
American Epilepsy Society (AES) meeting. During the double-blind
PROSPER study on Oxtellar XR, seizure control was maintained. In
addition, seizure control improved further during the long-term,
open-label, extension study when dosages could be optimized.
Oxtellar XR was also well tolerated during long-term maintenance
Supernus has an agreement with Patheon Inc. for the
manufacture, formulation, development and supply of
commercial-grade quantities of oxcarbazepine, the active
pharmaceutical ingredient in Supernus' Oxtellar XR, in the
Supernus carries a Zacks Rank #3 (Hold). Other players in the
pharma industry, which look attractive at current levels, include
Sucampo Pharmaceuticals Inc.
PharmaTech (Cayman) Inc.
Forest Laboratories Inc.
). All the three stocks carry a Zacks Rank #1 (Strong Buy).
FOREST LABS A (FRX): Free Stock Analysis
SUCAMPO PHARMAC (SCMP): Free Stock Analysis
SUPERNUS PHARMA (SUPN): Free Stock Analysis
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.